Compare TNYA & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNYA | MSLE |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 146.9M |
| IPO Year | 2021 | N/A |
| Metric | TNYA | MSLE |
|---|---|---|
| Price | $0.71 | $6.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.33 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 31.4K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.96 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $5.44 |
| 52 Week High | $2.35 | $13.39 |
| Indicator | TNYA | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 58.62 |
| Support Level | $0.65 | $6.71 |
| Resistance Level | $0.82 | $8.59 |
| Average True Range (ATR) | 0.04 | 0.34 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 44.10 | 87.36 |
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.